Podcast appearances and mentions of Rodney Dangerfield

Joel McHale joins Mark and Sam to throw back some drinks and dive into a wild one—swapping stories about Rodney Dangerfield and Paul Reubens, breaking down cancel culture and Demolition Man predictions, and reminiscing on stage life, reality TV chaos, and hair transplant regrets. Plus, Joel dishes behind-the-scenes moments with Seth MacFarlane, Mark Wahlberg, and the highs and lows of being a Hollywood extrovert. Sponsored by:

Step onto the field with us as we revisit "Ladybugs," the 1992 sports comedy starring the one and only Rodney Dangerfield. We'll unpack the story of a desperate salesman who coaches his company's girls' soccer team and resorts to some seriously questionable (and funny) tactics involving cross-dressing. Join us for a look back at this 90s classic, its comedic highs and lows, and how it reflects the humor of its time.Ladybugs movie, Rodney Dangerfield, 1990s comedy, girls soccer, cross dressing comedy.

Visit: RadioLawTalk.com for information & full episodes! Follow us on Facebook: bit.ly/RLTFacebook Follow us on Twitter: bit.ly/RLTTwitter Follow us on Instagram: bit.ly/RLTInstagram Subscribe to our YouTube channel: www.youtube.com/channel/UC3Owf1BEB-klmtD_92-uqzg Your Radio Law Talk hosts are exceptional attorneys and love what they do! They take breaks from their day jobs and make time for Radio Law Talk so that the rest of the country can enjoy the law like they do. Follow Radio Law Talk on Youtube, Facebook, Twitter & Instagram!

All movie geeks have those movies that we've purchased down at the used DVD store, but just haven't gotten around to watching yet. So this week Todd shares some thoughts on four movies that have been sitting on the shelf for a while, which he finally got around to watching. We start with an early appearance by Rosario Dawson in The First 20 Million is Always the Hardest. Next we go back to the 60's as Sandra Dee and Bobby Darin star in If a Man Answers. After that we look at one of the last films to star Rodney Dangerfield, The 4th Tenor. Then we close things out with the coming-of-age drama Staying Together. We also have some trivia questions along the way, and still make time for a movie recommendation to close the show. 

Author Michael Starr joins WGN Radio's Dave Plier to talk about his latest biography, Nothing Comes Easy: The Life of Rodney Dangerfield, the first-ever biography of the legendary comic and the most improbable rise to fame in the history of American comedy.

WGN Radio's Dave Plier showcases stand-up comedians with Chicago's Own Pat McGann, Roastmaster General Jeff Ross, Nikki Glaser, Harvey Illinois' own Tom Dreesen, Tom Papa, Jake Johannsen. Dave also talks to author Michael Starr on his new book: ‘Nothing Comes Easy: The Life of Rodney Dangerfield and Kelly Carlin on the legacy of her late […]

In this episode of the Better Learning Podcast, we're breaking down the 1986 comedy Back to School, where Rodney Dangerfield plays a loud, lovable millionaire who enrolls in college to reconnect with his son and shakes up the entire campus in the process. Joined by guest Thea Wayburn from BRIC Architecture, host Kevin Stoller and co-host Carla Cummins take a deeper look at how the film portrays higher education, student life, and the meaning of "fitting in." Part of our ongoing series dissecting school-related movies, we explore what this over-the-top comedy reveals (intentionally or not) about learning environments, relationships, and how schools support, or fail to support, belonging and growth.   Takeaways: Rodney Dangerfield's character may be unconventional, but his experience highlights the importance of creating inclusive environments where students of all backgrounds feel like they belong - something schools and universities are still working to get right today. While Back to School leans into comedy, it also touches on deeper issues like academic elitism, outdated teaching methods, and the value of real-world experience, sparking a conversation about what learning should look like in modern education. The movie challenges the idea that there's only one “right” way to succeed in education. We discuss how schools can better support alternative learners and value life experience alongside academic achievement.     About Thea Wayburn From finishes to space planning and furniture selection, Thea collaborates with project team members, consultants, district staff, and stakeholders to develop interior design solutions that enhance their school's design and align with the district's educational goals. Thea balances design expertise with end user advocacy to facilitate focus group sessions and synthesize feedback, creating spaces that reflect a learning community's unique identity.   Learn More About Thea Wayburn: LinkedIn: https://www.linkedin.com/in/thea-wayburn-9b3a16256/   Learn More About Pfluger Architects: Website: https://www.bric-arch.com/ Facebook: https://www.facebook.com/bric.arch Twitter: https://x.com/bric_arch Instagram: https://www.instagram.com/bric_arch/       Connect with host, Kevin Stoller: LinkedIn: https://www.linkedin.com/in/kevinstoller/   Connect with co-host, Carla Cummins: LinkedIn: https://www.linkedin.com/in/carla-cummins-01449659/   Learn More About Kay-Twelve: Website: https://kay-twelve.com/ LinkedIn: https://www.linkedin.com/company/kay-twelve-com/ Instagram: https://www.instagram.com/kay_twelve/       Episode 235 of the Better Learning Podcast Kevin Stoller is the host of the Better Learning Podcast and Co-Founder of Kay-Twelve, a national leader for educational furniture. Learn more about creating better learning environments at www.Kay-Twelve.com.     For more information on our partners: Association for Learning Environments (A4LE) - https://www.a4le.org/ Education Leaders' Organization - https://www.ed-leaders.org/ Second Class Foundation - https://secondclassfoundation.org/ EDmarket - https://www.edmarket.org/ Catapult @ Penn GSE - https://catapult.gse.upenn.edu/   Want to be a Guest Speaker? Request on our website

Paul Hickey, Co-Founder of Bespoke, breaks down the market action, as well as earnings from Asana and HPE. CrowdStrike earnings reaction with Joel Fishbein of Truist. Our Pippa Stevens on the latest in the warming relationship between nuclear and tech: this time, with Constellation and Meta. Stacy Rasgon of Bernstein on why Qualcomm is the “Rodney Dangerfield” of chip stocks—getting no respect despite strong fundamentals. Bullish technical signals with Warren Pies, Co-Founder of 3Fourteen Research, who sees a path to all-time highs this summer. Plus, Diana Olick on how more homeowners are cashing out home equity.

In this episode, I spoke with author Michael Seth Starr regarding his latest book "Nothin' Comes Easy: The Life of Rodney Dangerfield". Rodney Dangerfield's fidgety delivery, self-deprecating humor, and catchphrase “I don't get no respect” made him a comedy icon in nightclubs, on television, and in movies.

GGACP celebrates Bike to Work Week and National Bike Month by revisiting this memorable interview with veteran actor and environmentalist ED BEGLEY JR. In this episode, Ed talks about the glory days of the Troubadour, the timelessness of “The In-Laws,” the absurdity of Hollywood urban legends and the career of his Oscar-winning dad, Ed Begley. Also, Forrest Tucker takes a nip, Steve Allen checks into St. Eligius, Harry Belafonte shuts down Rodney Dangerfield and Ed hits the rink with Charlie's Angels. PLUS: Wheeler & Woolsey! “Amazon Women on the Moon”! Mr. Warmth lowers the boom! Ed remembers his friend Peter Falk! And the unsolved death of John “Stumpy” Pepys!  Learn more about your ad choices. Visit megaphone.fm/adchoices

Alan Zweibel Live on Game Changers With Vicki Abelson Live from the Zoom Room, it's Alan Zweibel! It was so great to jump back in with the fabulous, funny, and fun Emmy Winner. Alan took us back to his earliest days in the biz, how he made his way in, the first joke he sold, still funny! The Catskill Mountains, Morty Gunty, Freddie Roman, Rodney Dangerfield, maybe his first collaborator… with whom Alan comes full circle, presently. Doing standup with Billy Crystal, leading to years of collaboration, being discovered by Lorne Michaels… SNL, Alan's game changer. Gilda, a partnership made in heaven - how Roseannne Roseannadanna and Emily Latella came to be, Belushi, Ackroyd, the current film, Saturday Night, where it felt right, where liberties were taken, how it felt to have someone play him. Co-creating It's The Garry Shandling Show with Gary, how they worked together. Writing Lunatics with Dave Barry, long distance, For This We left Egypt with Dave and Adam Mansbach, and a great story about how that friendship and collaboration began. Broadway with Billy and with Martin Short, and the cute, sweet note after their encounter at the SNL 50th reunion. Alan's current collab with Barry Levinson, how that started and where it is today, that full circle Rodney story coming to fruition currently… and through it all, Robin. Alan's love and wife since the early SNL days… and his most fruitful collaborator. Alan's devotion to his family is what stories are made of, as is his work ethic, resiliency, tenacity, and talent. His storytelling is what good conversations are made of, served up with laughs, lots of them. What an inspiration! Loved every minute of this. And I sure did need the eggs. Alan Zweibel Live on Game Changers With Vicki Abelson Wednesday, 5/14/23, 5 pm PT, 8 pm ET Streamed Live Links in the comments Replay on YouTube https://www.youtube.com/watch?v=u1uvKClTYdY

Matt Crawford joins the show to discuss White Sox fan etiquette when going to Wrigley Field, who's the Yoan Moncada (aka Rodney Dangerfield) of this current Sox club and doesn't get enough respect, which prospects he's ready to #Promote and MUCH MUCH MORE. SPONSORED BY PUNKY'S PIZZA AND PASTA!! Follow Matt on Twitter https://x.com/Mattheius2783 Order from Punky's https://punkyspizza.com/ Buy 108 Merch https://fromthe108.bigcartel.com/prod...

Comedy has been a passion of mine for 20 years running. My intro to stand up was the first days of Youtube, Dave Chappelle had bits of his first specials. The first full stand up special I saw was Katt Williams Pimp Chronicles Part 1, I watched the full special with bonus features in a hotel on HBO. Snoop Dogg's cameo is unbelievable. Starting around 2015 I started listening to Joey Diaz' podcast and that is what really snowballed my love for stand up. The business side, the fellowship of comedy, the horrifying sad side of it all. More than likely, your favorite comedian has a heart breaking story about their life behind the scenes. Chris Farley was self conscious about his weight and didn't believe that anybody loved him. Rodney Dangerfield's own mother belittled and demeaned him to the point of permanent psychological damage. Joey Diaz, while tripping on a hit of LSD at 16 years old, found his mother with a purple arm, dead on the kitchen floor from a major heart attack. All three guys at one time were the best working comedian in the world. It isn't the ability to make a random human giggle for a second. It's the power to turn darkness into light. As always, thank you for being here.. Next weekend the show goes on like normalYour fav internet disc jockey,Johnny Joke Book

Its only been a few weeks since the first ever nuclear meltdown in United States history but that doesn't stop SNL from using it as inspiration for one of the most epic & outstanding sketches of the original era. Richard Benjamin, giving off strong Buck Henry vibes, takes the reins for a Saturday Night Live outing that is – while short on quantity – quite high on quality.We may not get many bits this episode, but almost all the ones we do get deliver. John Belushi's absence! The Nerds! Chico Escuela's comeback! A Rodney Dangerfield cameo?!! Indeed, there is still A LOT to talk about.Our old friend, Ian Fermaglich from Ian Talks Comedy, makes his return to The Early Years to drop some knowledge on Roseanne Rosannadanna, the Mets, and goes REAL deep on the host. Perhaps…too deep?Also…Rickie Lee Jones is the musical guest.---------------------------------Subscribe today!Follow us on social media: X (Twitter): NR4PTProjectBluesky: nr4ptproject.bsky.socialInstagram: nr4ptprojectFacebook: The Not Ready for Prime Time ProjectContact Us: Website: https://www.nr4project.comEmail: nr4ptproject@gmail.com

Michael Seth Starr is the author of Nothin' Comes Easy: The Life of Rodney DangerfieldMichael shares:-Different generations know Rodney for different things: Carson, Caddyshack, Back to School-Rodney quit comedy to sell aluminum siding  -How he got the name Rodney Dangerfield -Where did "I get no respect" come from "It was the era of the Godfather.  Rodney was working in a club, you heard some mobster-type people talking about getting no respect. He latched on to the "no respect" which is such a universal feeling, because everybody feels that way"-When he did Caddyshack he was almost 60!  "The role of Al Czervik (Caddyshack role) was offered to Bob Newhart, who didn't think it was funny! And Don Rickles who didn't want to do it, it wasn't his thing!""-'Back to School' with Sam and helping Jim Carrey   To subscribe to The Pete McMurray Show Podcast just click here

NOTHIN' COMES EASY: The Life of Rodney Dangerfield (April 29, 2025) is the first biography of the "bug-eyed, sweaty, herky-jerky, tie-pulling comedian with the doleful countenance." Dangerfield's indelible beat-down image was played for laughs, but there were sad truths behind his sad-sack persona. TV writer Michael Seth Starr has crafted an immensely entertaining bio of the comedian's slog up the show business ladder. Ten years as a C-level stand-up comedian, he quit the business to sell aluminum siding and paint to keep the lights on. Then he went back to the clubs under an entirely new name, from Jack Roy to Rodney Dangerfield. A career-changing appearance on The Ed Sullivan Show at the ripe age of forty-five would be the lucky break, opening doors to television, movies, and comic fame at last. His catch phrase, "I don't get no respect," underscored his circuitous rise to the top after years of setbacks and grit. "What stood out for me, in authoring this book," writes Starr, '"was Dangerfield's perseverance in the face of such overwhelming odds. I was impressed at how he launched a second comedy career as a man already in his forties and out of the game for a decade. He never abandoned his undeniable urge to get back in the game and to share his seemingly unending reservoir of magical one-liners." At the beginning of his comeback, he began writing jokes for comedians like Jackie Mason and Joey Bishop, in the days before the "no respect" persona was solidified. He worked agentless, making his own deals. And it took him a solid five years to clinch his now celebrated debut on The Ed Sullivan Show. It took another few years of hustling on the circuit before he landed on Johnny Carson's Tonight Show, which opened a wealth of doors in Hollywood. Dangerfield's comedy style - a self-mocking angst, the comedy of the perpetual loser - was endearing and universal. He was the schlubby Everyman snubbed by life, finally making it big. Soon Dangerfield would be leaving his mark in films, most famously in Caddyshack and Back to School. He was rebuffed in later years by The Academy of Motion Picture Arts and Sciences - which refused him membership. But Dangerfield had already cemented his place in comedy history as a writer and performer. When he died in 2004, his death made international headlines. Among his pallbearers were George Carlin, Roseanne Barr, Chris Rock, Larry David, Andrew Dice Clay, Jon Lovitz, and Carl Reiner. The book closes with a highly engaging chapter, "Riffs on Rodney," with remembrances of the comic from his peers including Jay Leno, Rita Rudney, Bob Nelson, Robert Wuhl, and Pauly Shore. Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-like-it-s-live--4113802/support.

'Caddyshack', it turns out, is kind of a miracle of last-minute producer-led stitching together and salvaging, resulting in one of the more quotable films in comedy history.   Hard to believe that at the time, Chevy Chase, Bill Murray, and Rodney Dangerfield were not yet the massive film stars they'd become as a result of this movie.   This episode delves into the coke-fueled nonstop party that was this film's production, a production that would contribute to the untimely death of co-writer Doug Kenney on a cliff in Hawaii where he'd gone to dry out.  Doug's death was one of the first casualties of this scene due to drugs, soon followed by John Belushi's.

We dive deep into the life and career of the comedian who gets “no respect,” Rodney Dangerfield. Author Michael Seth Starr joins Comedy History101 to talk about his new biography Nothin' Comes Easy, revealing how Dangerfield clawed his way back into comedy at age 45, the origins of his famous catchphrase, how he rewrote his persona, and finally got the respect he deserved. From aluminum siding to The Ed Sullivan Show to Caddyshack, we trace the underdog rise of one of comedy's most iconic voices. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dana and Tom with returning guest, Joe Boukhari (Instagram - I'll Get to It When I Get to It; Letterboxd Film Commentator - @bagodonuts) revisit Caddyshack (1980): written and directed by Harold Ramis with Douglas Kenney and Brian Doyle Murray, music by Johnny Mandel, cinematography by Stevan Larner, starring Chevy Chase, Ted Knight, Rodney Dangerfield, and Bill Murray.Plot Summary: Bushwood Country Club: an opulent haven for the wealthy, where life revolves around pristine greens, exclusivity, and egos so inflated they could double as golf carts. But underneath the facade of luxury lies a clash of worlds—working-class caddies and eccentric groundskeepers versus snobby elites—and it's about to get hilariously out of control.Danny Noonan (Michael O'Keefe), a young caddy striving to secure his future, finds himself entangled in the club's tangled hierarchy, navigating manipulative judges, raucous millionaires, and life lessons from Ty Webb (Chevy Chase), a laid-back golfer with pearls of wisdom that sound like they came from a Zen koan written by Groucho Marx. Meanwhile, Carl Spackler (Bill Murray), the quirky groundskeeper, engages in an escalating war with a gopher so cunning it could win a philosophy debate.Add in Al Czervik (Rodney Dangerfield), whose outlandish behavior becomes a catalyst for chaos, and Bushwood transforms into the backdrop for a wild satire of class division, absurd ambition, and the universal search for meaning—through golf, naturally. The result? A comedy that skewers pretense and celebrates the unpredictability of life, all while leaving the audience wondering how a gopher became the most unstoppable force in the universe.Chapters:00:00 Introduction and Welcome Back, Joe Boukhari02:42 Cast and Background for Caddyshack06:19 Relationship(s) with Caddyshack09:12 What is Caddyshack About?13:54 Status of Comedy in Film24:48 Plot Summary for Caddyshack26:36 Did You Know?28:29 First Break29:26 What's Up with Joe Boukhari?32:02 The Stanley Rubric - Legacy45:03 The Stanley Rubric - Impact/Significance50:33 The Stanley Rubric - Novelty57:52 Second Break58:33 The Stanley Rubric - Classicness01:04:54 The Stanley Rubric - Rewatchability01:09:27 The Stanley Rubric - Audience Score and Final Total01:11:28 Remaining Questions for Caddyshack01:14:44 Thank You to Joe Boukhari and Remaining Thoughts01:18:17 CreditsGuest:Joe BoukhariInstagram - I'll Get to It When I Get to ItLetterboxd Film Commentator - @bagodonutsYou can also find this episode in full video on YouTube.You can now follow us on Instagram, Twitter, YouTube, or TikTok (@gmoatpodcast).For more on the original episode, go to: https://www.ronnyduncanstudios.com/post/caddyshack-1980For more on the episode, go to:

OK, with golf season fully underway, it's time to salute Caddyshack, one of the classic 1980s comedy that featured the directorial debut of Harold Ramis, the big screen breakthrough for Rodney Dangerfield, some arrogant Ted Knight, some crazed Bill Murray and a lineage that drew heavily from both Saturday Night Live and the National Lampoon. Don't worry too much about the plot -- it's merely a launchpad for comedy bits galore. Whether you're a hacker, a duffer, or a scratch golfer, Caddyshack has something for you. And if you are a real big fan, you can watch it wearing your "William Murray" golf gear and finish with a pint at the "Murray Brothers Caddyshack Restaurant" (yes it's real). As always, find extra clips below and thanks for sharing our shows. Want more Caddyshack? Bill Murray has had far larger roles over time, but he makes the most of his Caddyshack persona Carl Spackler, a groundskeeper who is just a little, shall we say, disturbed. https://youtu.be/X48G7Y0VWW4?si=QGiCSvUEMJQYbGRo Chevy Chase has never been better than as Ty Webb, a pro-level golfer who smirks his way through life. Here are some of Chevy's best bits. https://youtu.be/Al3Yt5gxExY?si=CwIlxkEJFpXJIbTG Rodney Dangerfield was the perfect choice to play Al Czervik, a loud, crass, and hilarious "slob" dropped in the middle of a bunch of country club "snobs". Here Al tries to goad the arrogant Judge Smalls (a brilliant Ted Knight) into a slice. https://youtu.be/RrOhjHC28PQ?si=MFzVjclP0mKa6fxi

Karin Winegar is a long-time journalist who recently completed a 30 + year labor of love when Horse Lovers – Unpacking The Female Fascination With Horses. Karins work has been featured in the New York Times, Conde Nast and The Western Horseman. Karins love for animals made her want to be a veterinarian and her love was eventually channeled to the written word. Karin was a reporter for the Minneapolis Star and along the way interviewed such heavyweights as Dick Cavett, Joan Rivers, Anthony Quinn and Rodney Dangerfield who wore a bathrobe to the interview! Horse Lovers – Unpacking The Female Fascination reveals women as risk takers, romantics, independents so much more. She untangles the roots of female horse craziness, sizes it up, assesses its causes and effects and explores in depth who women are and why women feel and do what they do. It is a trail of exaltations, adventures and inquiries. It is about a colorful worldwide culture, about vivid lives and about a unique form of love.  Sit back and enjoy!

In 1978, after Harold Ramis wrapped "Animal House", the director teamed up with pals Brian Doyle-Murray and Douglas Kenney, along with Chevy Chase, Bill Murray, Ted Knight, and the one and only, Rodney Dangerfield, to bring similar frathouse shenanigans to the clubhouse. Featuring legendary performances (many of which were completely improvised) plus an equally memorable soundtrack, this 80s flick came barreling into theaters the summer of 1980, and went on to become one of the most cherished comedies of all time. Widely considered to be one of the all-time funniest comedies ever assembled, the film about a young golf caddy (Michael O'Keefe) desperate to win a scholarship and turn his life around has been listed #71 on AFI's 100 Years...100 Laughs and #7 on AFI's Top 10 Sports Films. So grab your golf clubs, watch out for gopher holes, and remember to be the ball as Tim Williams and guest co-hosts, Nicolas Pepin and Chris McMichen discuss “Caddyshack” from 1980 on this episode of the 80s Flick Flashback Podcast.Here are some additional behind-the-scenes trivia we were unable to cover in this episode:Cindy Morgan revealed that the oil massage scene with Chevy Chase was entirely improvised. When Lacy exclaims, "You're crazy!" that was Morgan's authentic reaction to Chase dousing her with oil, which was also the case with Chase's reply, "That's what they said about the Son Of Sam.”Writer and producer Douglas Kenney died after the film was released. He fell off a cliff while vacationing in Hawaii. Kenney had experienced deep depression after the film's post-production, as much of the original story had been significantly altered in the editing room, and he was strongly opposed to the final addition of the gopher to the film.Sources:Wikipedia, IMDB, Box Office Mojohttps://www.mentalfloss.com/article/56693/15-things-you-might-not-know-about-caddyshackhttps://screenrant.com/caddyshack-movie-behind-scenes-making-of-trivia/Some sections were composed or edited by ChatGPT We'd love to hear your thoughts on our podcast! You can share your feedback with us via email or social media. Your opinions are incredibly valuable to us, and we'd be so grateful to know what you enjoyed about our show. If we missed anything or if you have any suggestions for 80s movies, we'd love to hear them too! If you're feeling extra supportive, you can even become a subscription member through "Buy Me A Coffee". For more details and other fun extensions of our podcast, check out this link. Thank you for your support!https://linktr.ee/80sFlickFlashback

GGACP celebrates April's National Humor Month by revisiting one of the funniest mini-episodes in the archive as pop culture historian Kliph and illustrator Drew Friedman join the boys to cover discuss the dark secrets of vaudeville, the tragic childhood of Eddie Cantor, the phenomenon of Martin & Lewis and the strange death of “Parkyakarkus.” Also, Bob Hope dons blackface, Jack Benny swipes his stage name, Don Knotts sends up Hugh Hefner and the mob releases a comedy album. PLUS: Batman & Rubin! “The Baileys of Balboa”! Rodney Dangerfield vs. the feds! Aunt Esther goes electric! And the angriest man in show business! Learn more about your ad choices. Visit megaphone.fm/adchoices

Author and former New York Post Television Columnist Michael Seth Starr talks to 'Ross Crystal Upfront' about his latest biography on the life of the legendary comedian Rodney Dangerfield.

Rodney Dangerfield once famously said, “golf courses and cemeteries are the biggest wastes of prime real estate.” We won't touch cemeteries in this episode, but we do talk about golf courses. Monte Anderson joins me as we discuss different ways of looking at so-called “obsolete” properties. As a teaser: Monte shares with me what I think is one of the most brilliant ideas I've heard about how to work with old or declining churches. You must listen to understand it.The whole discussion reminded me of something I wrote about years ago:About fifteen years ago, I remember reading a planning study for a corridor in Kansas City, Missouri, where I was living and working at the time. We were working with a client that had some redevelopment ideas in mind, and wanted to see what the officially-adopted plan recommended. Like many planning studies, it had a simple market analysis attached to it, with a look at recent trends in the real estate market and some projections for the future. As most planners know, this is typical plain-vanilla planning 101. The market study informs the plan recommendations, which eventually are codified into zoning and process.One thing in particular struck me at the time: the economist's report bemoaning the “substandard” lot sizes in the area. I had to read it a few times before it became clear the message was that any serious redevelopment would require purchase and combination of many lots into larger development parcels. The notion baked into this was the original lots, many of which were 50 feet wide and around 100 – 150 feet deep (some narrower, some wider), were too small to attract modern, big-boy development. If any developer was ever to be serious about investing, he or she would need something more like what is typical with modern real estate development products. What is typical? Often that means several acres of land in one parcel, so the site can be developed with the necessary large, singular building, sufficient parking, room for storm water improvements, landscaping and lighting. Even in an urban location, the bias toward suburban-style solutions was still very strong, but when urban buildings were desired the thought process was still only a large, single master developer could accomplish transformation. Frankly, most planners and economic developers didn't know of or trust a different model. The design and development professions still largely cling to this approach.Substandard, obsolete, these are words thrown around a lot by planners and economic development officials. But don't buy it. Every property can be repurposed or rethought. In fact, Monte is the only person that's ever made me look at an ugly strip mall and think, “yeah, I could make something cool with this.”Find more content on The Messy City on Kevin's Substack page.Music notes: all songs by low standards, ca. 2010. Videos here. If you'd like a CD for low standards, message me and you can have one for only $5.Intro: “Why Be Friends”Outro: “Fairweather Friend” Get full access to The Messy City at kevinklinkenberg.substack.com/subscribe

Chris and Amy discuss editing and censoring movies for television. Chris says he wants to see 'art' in its original form. Amy & Chris also discuss explicit lyrics in music.

#625 I have a personal story.

Jerry Minor joined me to discuss his first memory of seeing Johnny Cash TV; the Detroit Lions; playing Michael Jackson's glove; being a Jehovah's Witness; proselytizing; leaving the Church and starting comedy; going to a show to try stand up; going to his first comedy show; working in Second City Detroit, Chicago, and Toronto and the similarities and differences; Mr. Show; being hired on SNL in 2000 and moved to cast when Tim Meadows leaves; Grandmaster Rap; working with Eminem on first show; impressions of Billy Dee Williams and Al Sharpton; working with Dana Carvey; the Tom Green episode, Mena Suvari; XFL delays Jennifer Lopez episode; Conan O' Brien; playing Sharpton to Darrell Hammond's Jesse Jackson; being let go; the problem of being the new guy; writing and the song "Somebody's Fucking My Lady" with Craig Robinson; Rodney Dangerfield; Martin Short Show; Anchorman; Abbott Elementary; Beer League; Lucky Louie; working with Louis CK; being in Funny People by Judd Apatow; guys named Jerry; being on the 1st season of Bob's Burgers; Brickleberry: Howard Stern; Yucko the Clown and JD; directing at Second City; SNL's 50th anniversary; David Cross inspires new podcasrt "Playing to the Back of the Room"

Slugs are the Rodney Dangerfield of garden wildlife – our only interest is in exterminating them.  Yet as Dr. Jann Vendetti of the Los Angeles County Natural History Museum explains, they lead fascinating and, in many ways, very useful lives

Send us a textJoin former child star Moosie Drier and author Jonathan Rosen as they chat with legendary comedian Jeff Altman!Jeff discusses getting his start in comedy in the 70s and becoming friends with such people as David Letterman, his co-starring on the variety show Pink Lady, how his father's friendship with Houdini, how his uncle helped discover celebrities such as Jimmy Stewart and Joan Crawford, working on Easy Money with Rodney Dangerfield and Joe Pesci, & much more!Support the show

Send us a textJoin former child star Moosie Drier and author Jonathan Rosen as they chat with legendary comedian Jeff Altman!Jeff discusses getting his start in comedy in the 70s and becoming friends with such people as David Letterman, his co-starring on the variety show Pink Lady, how his father's friendship with Houdini, how his uncle helped discover celebrities such as Jimmy Stewart and Joan Crawford, working on Easy Money with Rodney Dangerfield and Joe Pesci, & much more!Support the show

Connor Hope, Austin King and Tuck Clarry offer immediate reactions to the bracket and Gonzaga's #8 seed draw after months of being told that predictive metrics would carry significant weight.

Rick Mitchell joined me to discuss Carol recognizing him from TMZ; writing a performing speeches in his past ; it really not being that hard to write a good speech; giving a good speech requires you know your audience; this book can help save you from listening to bad speeches; differences in different religious weddings; worst speeches are graduation and bar mitzvah; not being Jewish and everyone thinking he is; taking a DNA test to find he's half Jewish; attending UC Davis; working at Second City and Improv Olympic; SNL being a big impetus; Norm MacDonald, Rodney Dangerfield, Mitch Hedberg, and George Carlin; his style; writing for Yakov Smirnoff; trying stand up after killing at his high school graduation; corporate gigs; his career at TMZ; writing monologues for Ellen; having her voice before being hired; her being from New Orleans; backstage gossip; what hurt her was always saying "be nice"; telling stories; guest hosts; Eugene & Dan Levy were hard; Wanda Sykes & Jennifer Anniston were easy; Robert Downey Jr, his favorite and Jason Sudeikis

We analyze Rodney Dangerfield's 1980 Grammy Award winning album, No Respect. FOR ALL THINGS BLIND MIKEhttp://blindmike.netFOR ALL THINGS CRAIGGERShttp://www.verygoodshow.orgFOR ALL THINGS HACKRIDEhttp://hackridethedemon.comFOR ALL THINGS DJ ELECTRA FRYhttp://djelectrafry.com

Send us a textAt a recent fundraiser, I produced a show for a sold out 400 seat room in Placerville CA. The headliner was Dennis Blair; a comic/musician who has toured with Rodney Dangerfield, Joan Rivers, Barry Manilow, and for over 18 years with George Carlin.A very funny standup comic who you will hear here, is funny and a talented musician.Listen, Enjoy, & Share!Dennis Blair, a seasoned comedian with over four decades in the entertainment industry, has made a significant mark with his stand-up performances and writing talents. Known for co-writing the Rodney Dangerfield movie "Easy Money" and spending 18 years opening for George Carlin, Blair has proven his comedic prowess time and again. His recent stand-up comedy special in Placerville garnered high praise from host R. Scott Edwards, who emphasized Blair's impressive career and ability to connect with audiences. The sold-out show, which featured material on diverse topics such as song lyrics, reggae music, and Elvis Presley, left a lasting impression, reaffirming Blair's status as a seasoned and engaging performer.(00:00:21) "Dennis Blair's Stand-Up Comedy Showcase"(00:00:21) Blair's Hilarious Performance at Sold-out FundraiserSupport the showWebsite: Standup Comedy Podcast Network.com www.StandupComedyPodcastNetwork.com Free APP on all Apple & Android phones....check it out, podcast, jokes, blogs, and More!"NEW" Video Podcast: Tag Team Talent Podcast on Spotify & YouTube See your favorite comics and other performers...Fun!Please Write a Review: in-depth walk-through for leaving a review.Interested in Standup Comedy? Check out my books on Amazon..."20 Questions Answered about Being a Standup Comic""Be a Standup Comic...or just look like one"

Hank Gallo discusses producing and working with guests on The Daily Show with Jon Stewart and Craig Kilborn including Betty White , Ed McMahon, and Rodney Dangerfield, as well his work on Politically Incorrect with Bill Maher, and more.

Funding for the NIH and US biomedical research is imperiled at a momentous time of progress. Exemplifying this is the work of Dr. Anna Greka, a leading physician-scientist at the Broad Institute who is devoted to unlocking the mysteries of rare diseases— that cumulatively affect 30 million Americans— and finding cures, science supported by the NIH.A clip from our conversationThe audio is available on iTunes and Spotify. The full video is linked here, at the top, and also can be found on YouTube.Transcript with audio and external linksEric Topol (00:06):Well, hello. This is Eric Topol from Ground Truths, and I am really delighted to welcome today, Anna Greka. Anna is the president of the American Society for Clinical Investigation (ASCI) this year, a very prestigious organization, but she's also at Mass General Brigham, a nephrologist, a cell biologist, a physician-scientist, a Core Institute Member of the Broad Institute of MIT and Harvard, and serves as a member of the institute's Executive Leadership Team. So we got a lot to talk about of all these different things you do. You must be pretty darn unique, Anna, because I don't know any cell biologists, nephrologists, physician-scientist like you.Anna Greka (00:48):Oh, thank you. It's a great honor to be here and glad to chat with you, Eric.Eric Topol (00:54):Yeah. Well, I had the real pleasure to hear you speak at a November conference, the AI for Science Forum, which we'll link to your panel. Where I was in a different panel, but you spoke about your extraordinary work and it became clear that we need to get you on Ground Truths, so you can tell your story to everybody. So I thought rather than kind of going back from the past where you were in Greece and somehow migrated to Boston and all that. We're going to get to that, but you gave an amazing TED Talk and it really encapsulated one of the many phenomenal stories of your work as a molecular sleuth. So maybe if you could give us a synopsis, and of course we'll link to that so people could watch the whole talk. But I think that Mucin-1 or MUC1, as you call it, discovery is really important to kind of ground our discussion.A Mysterious Kidney Disease Unraveled Anna Greka (01:59):Oh, absolutely. Yeah, it's an interesting story. In some ways, in my TED Talk, I highlight one of the important families of this story, a family from Utah, but there's also other important families that are also part of the story. And this is also what I spoke about in London when we were together, and this is really sort of a medical mystery that initially started on the Mediterranean island of Cyprus, where it was found that there were many families in which in every generation, several members suffered and ultimately died from what at the time was a mysterious kidney disease. This was more than 30 years ago, and it was clear that there was something genetic going on, but it was impossible to identify the gene. And then even with the advent of Next-Gen sequencing, this is what's so interesting about this story, it was still hard to find the gene, which is a little surprising.Anna Greka (02:51):After we were able to sequence families and identify monogenic mutations pretty readily, this was still very resistant. And then it actually took the firepower of the Broad Institute, and it's actually from a scientific perspective, an interesting story because they had to dust off the old-fashioned Sanger sequencing in order to get this done. But they were ultimately able to identify this mutation in a VNTR region of the MUC1 gene. The Mucin-1 gene, which I call a dark corner of the human genome, it was really, it's highly repetitive, very GC-rich. So it becomes very difficult to sequence through there with Next-Gen sequencing. And so, ultimately the mutation of course was found and it's a single cytosine insertion in a stretch of cytosines that sort of causes this frameshift mutation and an early stop codon that essentially results in a neoprotein like a toxic, what I call a mangled protein that sort of accumulates inside the kidney cells.Anna Greka (03:55):And that's where my sort of adventure began. It was Eric Lander's group, who is the founding director of the Broad who discovered the mutation. And then through a conversation we had here in Boston, we sort of discovered that there was an opportunity to collaborate and so that's how I came to the Broad, and that's the beginnings of this story. I think what's fascinating about this story though, that starts in a remote Mediterranean island and then turns out to be a disease that you can find in every continent all over the world. There are probably millions of patients with kidney disease in whom we haven't recognized the existence of this mutation. What's really interesting about it though is that what we discovered is that the mangled protein that's a result of this misspelling of this mutation is ultimately captured by a family of cargo receptors, they're called the TMED cargo receptors and they end up sort of grabbing these misfolded proteins and holding onto them so tight that it's impossible for the cell to get rid of them.Anna Greka (04:55):And they become this growing heap of molecular trash, if you will, that becomes really hard to manage, and the cells ultimately die. So in the process of doing this molecular sleuthing, as I call it, we actually also identified a small molecule that actually disrupts these cargo receptors. And as I described in my TED Talk, it's a little bit like having these cargo trucks that ultimately need to go into the lysosome, the cells recycling facility. And this is exactly what this small molecule can do. And so, it was just like a remarkable story of discovery. And then I think the most exciting of all is that these cargo receptors turn out to be not only relevant to this one mangled misshapen protein, but they actually handle a completely different misshapen protein caused by a different genetic mutation in the eye, causing retinitis pigmentosa, a form of blindness, familial blindness. We're now studying familial Alzheimer's disease that's also involving these cargo receptors, and there are other mangled misshapen proteins in the liver, in the lung that we're now studying. So this becomes what I call a node, like a nodal mechanism that can be targeted for the benefit of many more patients than we had previously thought possible, which has been I think, the most satisfying part about this story of molecular sleuthing.Eric Topol (06:20):Yeah, and it's pretty extraordinary. We'll put the figure from your classic Cell paper in 2019, where you have a small molecule that targets the cargo receptor called TMED9.Anna Greka (06:34):Correct.Expanding the MissionEric Topol (06:34):And what's amazing about this, of course, is the potential to reverse this toxic protein disease. And as you say, it may have applicability well beyond this MUC1 kidney story, but rather eye disease with retinitis pigmentosa and the familial Alzheimer's and who knows what else. And what's also fascinating about this is how, as you said, there were these limited number of families with the kidney disease and then you found another one, uromodulin. So there's now, as you say, thousands of families, and that gets me to part of your sleuth work is not just hardcore science. You started an entity called the Ladders to Cures (L2C) Scientific Accelerator.Eric Topol (07:27):Maybe you can tell us about that because this is really pulling together all the forces, which includes the patient advocacy groups, and how are we going to move forward like this?Anna Greka (07:39):Absolutely. I think the goal of the Ladders to Cures Accelerator, which is a new initiative that we started at the Broad, but it really encompasses many colleagues across Boston. And now increasingly it's becoming sort of a national, we even have some international collaborations, and it's only two years that it's been in existence, so we're certainly in a growth mode. But the inspiration was really some of this molecular sleuthing work where I basically thought, well, for starters, it cannot be that there's only one molecular node, these TMED cargo receptors that we discovered there's got to be more, right? And so, there's a need to systematically go and find more nodes because obviously as anyone who works in rare genetic diseases will tell you, the problem for all of us is that we do what I call hand to hand combat. We start with the disease with one mutation, and we try to uncover the mechanism and then try to develop therapies, and that's wonderful.Anna Greka (08:33):But of course, it's slow, right? And if we consider the fact that there are 30 million patients in the United States in every state, everywhere in the country who suffer from a rare genetic disease, most of them, more than half of them are children, then we can appreciate the magnitude of the problem. Out of more than 8,000 genes that are involved in rare genetic diseases, we barely have something that looks like a therapy for maybe 500 of them. So there's a huge mismatch in the unmet need and magnitude of the problem. So the Ladders to Cures Accelerator is here to address this and to do this with the most modern tools available. And to your point, Eric, to bring patients along, not just as the recipients of whatever we discover, but also as partners in the research enterprise because it's really important to bring their perspectives and of course their partnerships in things like developing appropriate biomarkers, for example, for what we do down the road.Anna Greka (09:35):But from a fundamental scientific perspective, this is basically a project that aims to identify every opportunity for nodes, underlying all rare genetic diseases as quickly as possible. And this was one of the reasons I was there at the AI for Science Forum, because of course when one undertakes a project in which you're basically, this is what we're trying to do in the Ladders to Cures Accelerator, introduce dozens of thousands of missense and nonsense human mutations that cause genetic diseases, simultaneously introduce them into multiple human cells and then use modern scalable technology tools. Things like CRISPR screens, massively parallel CRISPR screens to try to interrogate all of these diseases in parallel, identify the nodes, and then develop of course therapeutic programs based on the discovery of these nodes. This is a massive data generation project that is much needed and in addition to the fact that it will help hopefully accelerate our approach to all rare diseases, genetic diseases. It is also a highly controlled cell perturbation dataset that will require the most modern tools in AI, not only to extract the data and understand the data of this dataset, but also because this, again, an extremely controlled, well controlled cell perturbation dataset can be used to train models, train AI models, so that in the future, and I hope this doesn't sound too futuristic, but I think that we're all aiming for that cell biologists for sure dream of this moment, I think when we can actually have in silico the opportunity to make predictions about what cell behaviors are going to look like based on a new perturbation that was not in the training set. So an experiment that hasn't yet been done on a cell, a perturbation that has not been made on a human cell, what if like a new drug, for example, or a new kind of perturbation, a new chemical perturbation, how would it affect the behavior of the cell? Can we make a predictive model for that? This doesn't exist today, but I think this is something, the cell prediction model is a big question for biology for the future. And so, I'm very energized by the opportunity to both address this problem of rare monogenic diseases that remains an unmet need and help as many patients as possible while at the same time advancing biology as much as we possibly can. So it's kind of like a win-win lifting all boats type of enterprise, hopefully.Eric Topol (12:11):Yeah. Well, there's many things to get to unpack what you've just been reviewing. So one thing for sure is that of these 8,000 monogenic diseases, they have relevance to the polygenic common diseases, of course. And then also the fact that the patient family advocates, they are great at scouring the world internet, finding more people, bringing together communities for each of these, as you point out aptly, these rare diseases cumulatively are high, very high proportion, 10% of Americans or more. So they're not so rare when you think about the overall.Anna Greka (12:52):Collectively.Help From the Virtual Cell?Eric Topol (12:53):Yeah. Now, and of course is this toxic proteinopathies, there's at least 50 of these and the point that people have been thinking until now that, oh, we found a mangled protein, but what you've zeroed in on is that, hey, you know what, it's not just a mangled protein, it's how it gets stuck in the cell and that it can't get to the lysosome to get rid of it, there's no waste system. And so, this is such fundamental work. Now that gets me to the virtual cell story, kind of what you're getting into. I just had a conversation with Charlotte Bunne and Steve Quake who published a paper in December on the virtual cell, and of course that's many years off, but of course it's a big, bold, ambitious project to be able to say, as you just summarized, if you had cells in silico and you could do perturbations in silico, and of course they were validated by actual experiments or bidirectionally the experiments, the real ones helped to validate the virtual cell, but then you could get a true acceleration of your understanding of cell biology, your field of course.Anna Greka (14:09):Exactly.Eric Topol (14:12):So what you described, is it the same as a virtual cell? Is it kind of a precursor to it? How do you conceive this because this is such a complex, I mean it's a fundamental unit of life, but it's also so much more complex than a protein or an RNA because not only all the things inside the cell, inside all these organelles and nucleus, but then there's all the outside interactions. So this is a bold challenge, right?Anna Greka (14:41):Oh my god, it's absolutely from a biologist perspective, it's the challenge of a generation for sure. We think taking humans to Mars, I mean that's an aspirational sort of big ambitious goal. I think this is the, if you will, the Mars shot for biology, being able to, whether the terminology, whether you call it a virtual cell. I like the idea of saying that to state it as a problem, the way that people who think about it from a mathematics perspective for example, would think about it. I think stating it as the cell prediction problem appeals to me because it actually forces us biologists to think about setting up the way that we would do these cell perturbation data sets, the way we would generate them to set them up to serve predictions. So for example, the way that I would think about this would be can I in the future have so much information about how cell perturbations work that I can train a model so that it can predict when I show it a picture of another cell under different conditions that it hasn't seen before, that it can still tell me, ah, this is a neuron in which you perturbed the mitochondria, for example, and now this is sort of the outcome that you would expect to see.Anna Greka (16:08):And so, to be able to have this ability to have a model that can have the ability to predict in silico what cells would look like after perturbation, I think that's sort of the way that I think about this problem. It is very far away from anything that exists today. But I think that the beginning starts, and this is one of the unique things about my institute, if I can say, we have a place where cell biologists, geneticists, mathematicians, machine learning experts, we all come together in the same place to really think and grapple with these problems. And of course we're very outward facing, interacting with scientists all across the world as well. But there's this sort of idea of bringing people into one institute where we can just think creatively about these big aspirational problems that we want to solve. I think this is one of the unique things about the ecosystem at the Broad Institute, which I'm proud to be a part of, and it is this kind of out of the box thinking that will hopefully get us to generate the kinds of data sets that will serve the needs of building these kinds of models with predictive capabilities down the road.Anna Greka (17:19):But as you astutely said, AlphaFold of course was based on the protein database existing, right? And that was a wealth of available information in which one could train models that would ultimately be predictive, as we have seen this miracle that Demi Hassabis and John Jumper have given to humanity, if you will.Anna Greka (17:42):But as Demis and John would also say, I believe is as I have discussed with them, in fact, the cell prediction problem is really a bigger problem because we do not have a protein data bank to go to right now, but we need to create it to generate these data. And so, my Ladders to Cures Accelerator is here to basically provide some part of the answer to that problem, create this kind of well-controlled database that we need for cell perturbations, while at the same time maximizing our learnings about these fully penetrant coding mutations and what their downstream sequelae would be in many different human cells. And so, in this way, I think we can both advance our knowledge about these monogenic diseases, build models, hopefully with predictive capabilities. And to your point, a lot of what we will learn about this biology, if we think that it involves 8,000 or more out of the 20,000 genes in our genome, it will of course serve our understanding of polygenic diseases ultimately as well as we go deeper into this biology and we look at the combinatorial aspects of what different mutations do to human cells. And so, it's a huge aspirational problem for a whole generation, but it's a good one to work on, I would say.Learning the Language of Life with A.I. Eric Topol (19:01):Oh, absolutely. Now I think you already mentioned something that's quite, well, two things from what you just touched on. One of course, how vital it is to have this inner or transdisciplinary capability because you do need expertise across these vital areas. But the convergence, I mean, I love your term nodal biology and the fact that there's all these diseases like you were talking about, they do converge and nodal is a good term to highlight that, but it's not. Of course, as you mentioned, we have genome editing which allows to look at lots of different genome perturbations, like the single letter change that you found in MUC1 pathogenic critical mutation. There's also the AI world which is blossoming like I've never seen. In fact, I had in Science this week about learning the language of life with AI and how there's been like 15 new foundation models, DNA, proteins, RNA, ligands, all their interactions and the beginning of the cell story too with the human cell.Eric Topol (20:14):So this is exploding. As you said, the expertise in computer science and then this whole idea that you could take these powerful tools and do as you said, which is the need to accelerate, we just can't sit around here when there's so much discovery work to be done with the scalability, even though it might take years to get to this artificial intelligence virtual cell, which I have to agree, everyone in biology would say that's the holy grail. And as you remember at our conference in London, Demi Hassabis said that's what we'd like to do now. So it has the attention of leaders in AI around the world, obviously in the science and the biomedical community like you and many others. So it is an extraordinary time where we just can't sit still with these tools that we have, right?Anna Greka (21:15):Absolutely. And I think this is going to be, you mentioned the ASCI presidency in the beginning of our call. This is going to be the president gets to give an address at the annual meeting in Chicago. This is going to be one of the points I make, no matter what field in biomedicine we're in, we live in, I believe, a golden era and we have so many tools available to us that we can really accelerate our ability to help more patients. And of course, this is our mandate, the most important stakeholders for everything that we do as physician-scientists are our patients ultimately. So I feel very hopeful for the future and our ability to use these tools and to really make good on the promise of research is a public good. And I really hope that we can advance our knowledge for the benefit of all. And this is really an exciting time, I think, to be in this field and hopefully for the younger colleagues a time to really get excited about getting in there and getting involved and asking the big questions.Career ReflectionsEric Topol (22:21):Well, you are the prototype for this and an inspiration to everyone really, I'm sure to your lab group, which you highlighted in the TED Talk and many other things that you do. Now I want to spend a little bit of time about your career. I think it's fascinating that you grew up in Greece and your father's a nephrologist and your mother's a pathologist. So you had two physicians to model, but I guess you decided to go after nephrology, which is an area in medicine that I kind of liken it to Rodney Dangerfield, he doesn't get any respect. You don't see many people that go into nephrology. But before we get to your decision to do that somehow or other you came from Greece to Harvard for your undergrad. How did you make that connect to start your college education? And then subsequently you of course you stayed in Boston, you've never left Boston, I think.Anna Greka (23:24):I never left. Yeah, this is coming into 31 years now in Boston.Anna Greka (23:29):Yeah, I started as a Harvard undergraduate and I'm now a full professor. It's kind of a long, but wonderful road. Well, actually I would credit my parents. You mentioned that my father, they're both physician-scientists. My father is now both retired, but my father is a nephrologist, and my mother is a pathologist, actually, they were both academics. And so, when we were very young, we lived in England when my parents were doing postdoctoral work. That was actually a wonderful gift that they gave me because I became bilingual. It was a very young age, and so that allowed me to have this advantage of being fluent in English. And then when we moved back to Greece where I grew up, I went to an American school. And from that time, this is actually an interesting story in itself. I'm very proud of this school.Anna Greka (24:22):It's called Anatolia, and it was founded by American missionaries from Williams College a long time ago, 150 and more years ago. But it is in Thessaloniki, Greece, which is my hometown, and it's a wonderful institution, which gave me a lot of gifts as well, preparing me for coming to college in the United States. And of course, I was a good student in high school, but what really was catalytic was that I was lucky enough to get a scholarship to go to Harvard. And that was really, you could say the catalyst that propelled me from a teenager who was dreaming about a career as a physician-scientist because I certainly was for as far back as I remember in fact. But then to make that a reality, I found myself on the Harvard campus initially for college, and then I was in the combined Harvard-MIT program for my MD PhD. And then I trained in Boston at Mass General in Brigham, and then sort of started my academic career. And that sort of brings us to today, but it is an unlikely story and one that I feel still very lucky and blessed to have had these opportunities. So for sure, it's been wonderful.Eric Topol (25:35):We're the ones lucky that you came here and set up shop and you did your productivity and discovery work and sleuthing has been incredible. But I do think it's interesting too, because when you did your PhD, it was in neuroscience.Anna Greka (25:52):Ah, yes. That's another.Eric Topol (25:54):And then you switch gears. So tell us about that?Anna Greka (25:57):This is interesting, and actually I encourage more colleagues to think about it this way. So I have always been driven by the science, and I think that it seems a little backward to some people, but I did my PhD in neuroscience because I was interested in understanding something about these ion channels that were newly discovered at the time, and they were most highly expressed in the brain. So here I was doing work in the brain in the neuroscience program at Harvard, but then once I completed my PhD and I was in the middle of my residency training actually at Mass General, I distinctly remember that there was a paper that came out that implicated the same family of ion channels that I had spent my time understanding in the brain. It turned out to be a channelopathy that causes kidney disease.Anna Greka (26:43):So that was the light bulb, and it made me realize that maybe what I really wanted to do is just follow this thread. And my scientific curiosity basically led me into studying the kidney and then it seemed practical therefore to get done with my clinical training as efficiently as possible. So I finished residency, I did nephrology training, and then there I was in the lab trying to understand the biology around this channelopathy. And that sort of led us into the early projects in my young lab. And in fact, it's interesting we didn't talk about that work, but that work in itself actually has made it all the way to phase II trials in patients. This was a paper we published in Science in 2017 and follow onto that work, there was an opportunity to build this into a real drug targeting one of these ion channels that has made it into phase II trials. And we'll see what happens next. But it's this idea of following your scientific curiosity, which I also talked about in my TED Talk, because you don't know to what wonderful places it will lead you. And quite interestingly now my lab is back into studying familial Alzheimer's and retinitis pigmentosa in the eye in brain. So I tell people, do not limit yourself to whatever someone says your field is or should be. Just follow your scientific curiosity and usually that takes you to a lot more interesting places. And so, that's certainly been a theme from my career, I would say.Eric Topol (28:14):No, I think that's perfect. Curiosity driven science is not the term. You often hear hypothesis driven or now with AI you hear more AI exploratory science. But no, that's great. Now I want to get a little back to the AI story because it's so fascinating. You use lots of different types of AI such as cellular imaging would be fusion models and drug discovery. I mean, you've had drug discovery for different pathways. You mentioned of course the ion channel and then also as we touched on with your Cell paper, the whole idea of targeting the cargo receptor with a small molecule and then things in between. You discussed this of course at the London panel, but maybe you just give us the skinny on the different ways that you incorporate AI in the state-of-the-art science that you're doing?Anna Greka (29:17):Sure, yeah, thank you. I think there are many ways in which even for quite a long time before AI became such a well-known kind of household term, if you will, the concept of machine learning in terms of image processing is something that has been around for some time. And so, this is actually a form of AI that we use in order to process millions of images. My lab has by produced probably more than 20 million images over the last few years, maybe five to six years. And so, if you can imagine it's impossible for any human to process this many images and make sense of them. So of course, we've been using machine learning that is becoming increasingly more and more sophisticated and advanced in terms of being able to do analysis of images, which is a lot of what we cell biologists do, of course.Anna Greka (30:06):And so, there's multiple different kinds of perturbations that we do to cells, whether we're using CRISPR or base editing to make, for example, genome wide or genome scale perturbations or small molecules as we have done as well in the past. These are all ways in which we are then using machine learning to read out the effects in images of cells that we're looking at. So that's one way in which machine learning is used in our daily work, of course, because we study misshape and mangled proteins and how they are recognized by these cargo receptors. We also use AlphaFold pretty much every day in my lab. And this has been catalytic for us as a tool because we really are able to accelerate our discoveries in ways that were even just three or four years ago, completely impossible. So it's been incredible to see how the young people in my lab are just so excited to use these tools and they're becoming extremely savvy in using these tools.Anna Greka (31:06):Of course, this is a new generation of scientists, and so we use AlphaFold all the time. And this also has a lot of implications of course for some of the interventions that we might think about. So where in this cargo receptor complex that we study for example, might we be able to fit a drug that would disrupt the complex and lead the cargo tracks into the lysosome for degradation, for example. So there's many ways in which AI can be used for all of these functions. So I would say that if we were to organize our thinking around it, one way to think about the use of machine learning AI is around what I would call understanding biology in cells and what in sort of more kind of drug discovery terms you would call target identification, trying to understand the things that we might want to intervene on in order to have a benefit for disease.Anna Greka (31:59):So target ID is one area in which I think machine learning and AI will have a catalytic effect as they already are. The other of course, is in the actual development of the appropriate drugs in a rational way. So rational drug design is incredibly enabled by AlphaFold and all these advances in terms of understanding protein structures and how to fit drugs into them of all different modalities and kinds. And I think an area that we are not yet harnessing in my group, but I think the Ladders to Cures Accelerator hopes to build on is really patient data. I think that there's a lot of opportunity for AI to be used to make sense of medical records for example and how we extract information that would tell us that this cohort of patients is a better cohort to enroll in your trial versus another. There are many ways in which we can make use of these tools. Not all of them are there yet, but I think it's an exciting time for being involved in this kind of work.Eric Topol (32:58):Oh, no question. Now it must be tough when you know the mechanism of these families disease and you even have a drug candidate, but that it takes so long to go from that to helping these families. And what are your thoughts about that, I mean, are you thinking also about genome editing for some of these diseases or are you thinking to go through the route of here's a small molecule, here's the tox data in animal models and here's phase I and on and on. Where do you think because when you know so much and then these people are suffering, how do you bridge that gap?Anna Greka (33:39):Yeah, I think that's an excellent question. Of course, having patients as our partners in our research is incredible as a way for us to understand the disease, to build biomarkers, but it is also exactly creating this kind of emotional conflict, if you will, because of course, to me, honesty is the best policy, if you will. And so, I'm always very honest with patients and their families. I welcome them to the lab so they can see just how long it takes to get some of these things done. Even today with all the tools that we have, of course there are certain things that are still quite slow to do. And even if you have a perfect drug that looks like it fits into the right pocket, there may still be some toxicity, there may be other setbacks. And so, I try to be very honest with patients about the road that we're on. The small molecule path for the toxic proteinopathies is on its way now.Anna Greka (34:34):It's partnered with a pharmaceutical company, so it's on its way hopefully to patients. Of course, again, this is an unpredictable road. Things can happen as you very well know, but I'm at least glad that it's sort of making its way there. But to your point, and I'm in an institute where CRISPR was discovered, and base editing and prime editing were discovered by my colleagues here. So we are in fact looking at every other modality that could help with these diseases. We have several hurdles to overcome because in contrast to the liver and the brain, the kidney for example, is not an organ in which you can easily deliver nucleic acid therapies, but we're making progress. I have a whole subgroup within the bigger group who's focusing on this. It's actually organized in a way where they're running kind of independently from the cell biology group that I run.Anna Greka (35:31):And it's headed by a person who came from industry so that she has the opportunity to really drive the project the way that it would be run milestone driven, if you will, in a way that it would be run as a therapeutics program. And we're really trying to go after all kinds of different nucleic acid therapies that would target the mutations themselves rather than the cargo receptors. And so, there's ASO and siRNA technologies and then also actual gene editing technologies that we are investigating. But I would say that some of them are closer than others. And again, to your question about patients, I tell them honestly when a project looks to be more promising, and I also tell them when a project looks to have hurdles and that it will take long and that sometimes I just don't know how long it will take before we can get there. The only thing that I can promise patients in any of our projects, whether it's Alzheimer's, blindness, kidney disease, all I can promise is that we're working the hardest we possibly can on the problem.Anna Greka (36:34):And I think that is often reassuring I have found to patients, and it's best to be honest about the fact that these things take a long time, but I do think that they find it reassuring that someone is on it essentially, and that there will be some progress as we move forward. And we've made progress in the very first discovery that came out of my lab. As I mentioned to you, we've made it all the way to phase II trials. So I have seen the trajectory be realized, and I'm eager to make it happen again and again as many times as I can within my career to help as many people as possible.The Paucity of Physician-ScientistsEric Topol (37:13):I have no doubts that you'll be doing this many times in your career. No, there's no question about it. It's extraordinary actually. There's a couple of things there I want to pick up on. Physician-scientists, as you know, are a rarefied species. And you have actually so nicely told the story about when you have a physician-scientist, you're caring for the patients that you're researching, which is, most of the time we have scientists. Nothing wrong with them of course, but you have this hinge point, which is really important because you're really hearing the stories and experiencing the patients and as you say, communicating about the likelihood of being able to come up with a treatment or the progress. What are we going to do to get more physician-scientists? Because this is a huge problem, it has been for decades, but the numbers just keep going lower and lower.Anna Greka (38:15):I think you're absolutely right. And this is again, something that in my leadership of the ASCI I have made sort of a cornerstone of our efforts. I think that it has been well-documented as a problem. I think that the pressures of modern clinical care are really antithetical to the needs of research, protected time to really be able to think and be creative and even have the funding available to be able to pursue one's program. I think those pressures are becoming so heavy for investigators that many of them kind of choose one or the other route most often the clinical route because that tends to be, of course where they can support their families better. And so, this has been kind of the conundrum in some ways that we take our best and brightest medical students who are interested in investigation, we train them and invest in them in becoming physician-scientists, but then we sort of drop them at the most vulnerable time, which is usually after one completes their clinical and scientific training.Anna Greka (39:24):And they're embarking on early phases of one's careers. It has been found to be a very vulnerable point when a lot of people are now in their mid-thirties or even late thirties perhaps with some family to take care of other burdens of adulthood, if you will. And I think what it becomes very difficult to sustain a career where one salary is very limited due to the research component. And so, I think we have to invest in our youngest people, and it is a real issue that there's no good mechanism to do that at the present time. So I was actually really hoping that there would be an opportunity with leadership at the NIH to really think about this. It's also been discussed at the level of the National Academy of Medicine where I had some role in discussing the recent report that they put out on the biomedical enterprise in the United States. And it's kind of interesting to see that there is a note made there about this issue and the fact that there needs to be, I think, more generous investment in the careers of a few select physician-scientists that we can support. So if you look at the numbers, currently out of the entire physician workforce, a physician-scientist comprised of less than 1%.Anna Greka (40:45):It's probably closer to 0.8% at this point.Eric Topol (40:46):No, it's incredible.Anna Greka (40:48):So that's really not enough, I think, to maintain the enterprise and if you will, this incredible innovation economy that the United States has had this miracle engine, if you will, in biomedicine that has been fueled in large part by physician investigators. Of course, our colleagues who are non-physician investigators are equally important partners in this journey. But we do need a few of the physician-scientists investigators I think as well, if you really think about the fact that I think 70% of people who run R&D programs in all the big pharmaceutical companies are physician-scientists. And so, we need people like us to be able to work on these big problems. And so, more investment, I think that the government, the NIH has a role to play there of course. And this is important from both an economic perspective, a competition perspective with other nations around the world who are actually heavily investing in the physician-scientist workforce.Anna Greka (41:51):And I think it's also important to do so through our smaller scale efforts at the ASCI. So one of the things that I have been involved in as a council member and now as president is the creation of an awards program for those early career investigators. So we call them the Emerging-Generation Awards, and we also have the Young Physician-Scientist Awards. And these are really to recognize people who are making that transition from being kind of a trainee and a postdoc and have finished their clinical training into becoming an independent assistant professor. And so, those are small awards, but they're kind of a symbolic tap on the shoulder, if you will, that the ASCI sees you, you're talented, stay the course. We want you to become a future member. Don't give up and please keep on fighting. I think that can take us only so far.Anna Greka (42:45):I mean, unless there's a real investment, of course still it will be hard to maintain people in the pipeline. But this is just one way in which we have tried to, these programs that the ASCI offers have been very successful over the last few years. We create a cohort of investigators who are clearly recognized by members of the ASCI is being promising young colleagues. And we give them longitudinal training as part of a cohort where they learn about how to write a grant, how to write a paper, leadership skills, how to run a lab. And they're sort of like a buddy system as well. So they know that they're in it together rather than feeling isolated and struggling to get their careers going. And so, we've seen a lot of success. One way that we measure that is conversion into an ASCI membership. And so, we're encouraged by that, and we hope that the program can continue. And of course, as president, I'm going to be fundraising for that as well, it's part of the role. But it is a really worthy cause because to your point, we have to somehow make sure that our younger colleagues stay the course that we can at least maintain, if not bolster our numbers within the scientific workforce.Eric Topol (43:57):Well, you outlined some really nice strategies and plans. It's a formidable challenge, of course. And we'd like to see billions of dollars to support this. And maybe someday we will because as you say, if we could relieve the financial concerns of people who have curiosity driven ideas.Anna Greka (44:18):Exactly.Eric Topol (44:19):We could do a lot to replenish and build a big physician-scientist workforce. Now, the last thing I want to get to, is you have great communication skills. Obviously, anybody who is listening or watching this.Eric Topol (44:36):Which is another really important part of being a scientist, no less a physician or the hybrid of the two. But I wanted to just go to the backstory because your TED Talk, which has been watched by hundreds of thousands of people, and I'm sure there's hundreds of thousands more that will watch it, but the TED organization is famous for making people come to the place a week ahead. This is Vancouver used to be in LA or Los Angeles area and making them rehearse the talk, rehearse, rehearse, rehearse, which seems crazy. You could train the people there, how to give a talk. Did you have to go through that?Anna Greka (45:21):Not really. I did rehearse once on stage before I actually delivered the talk live. And I was very encouraged by the fact that the TED folks who are of course very well calibrated, said just like that. It's great, just like that.Eric Topol (45:37):That says a lot because a lot of people that do these talks, they have to do it 10 times. So that kind of was another metric. But what I don't like about that is it just because these people almost have to memorize their talks from giving it so much and all this coaching, it comes across kind of stilted and unnatural, and you're just a natural great communicator added to all your other things.Anna Greka (46:03):I think it's interesting. Actually, I would say, if I may, that I credit, of course, I actually think that it's important, for us physician-scientists, again, science and research is a public good, and being able to communicate to the public what it is that we do, I think is kind of an obligation for the fact that we are funded by the public to do this kind of work. And so, I think that's important. And I always wanted to cultivate those communication skills for the benefit of communicating simply and clearly what it is that we do in our labs. But also, I would say as part of my story, I mentioned that I had the opportunity to attend a special school growing up in Greece, Anatolia, which was an American school. One of the interesting things about that is that there was an oratory competition.Anna Greka (46:50):I got very early exposure entering that competition. And if you won the first prize, it was in the kind of ancient Rome way, first among equals, right? And so, that was the prize. And I was lucky to have this early exposure. This is when I was 14, 15, 16 years old, that I was training to give these oratory speeches in front of an audience and sort of compete with other kids who were doing the same. I think these are just wonderful gifts that a school can give a student that have stayed with me for life. And I think that that's a wonderful, yeah, I credit that experience for a lot of my subsequent capabilities in this area.Eric Topol (47:40):Oh, that's fantastic. Well, this has been such an enjoyable conversation, Anna. Did I miss anything that we need to bring up, or do you think we have it covered?Anna Greka (47:50):Not at all. No, this was wonderful, and I thoroughly enjoyed it as well. I'm very honored seeing how many other incredible colleagues you've had on the show. It's just a great honor to be a part of this. So thank you for having me.Eric Topol (48:05):Well, you really are such a great inspiration to all of us in the biomedical community, and we'll be cheering for your continued success and thanks so much for joining today, and I look forward to the next time we get a chance to visit.Anna Greka (48:20):Absolutely. Thank you, Eric.**************************************Thanks for listening, watching or reading Ground Truths. Your subscription is greatly appreciated.If you found this podcast interesting please share it!That makes the work involved in putting these together especially worthwhile.All content on Ground Truths—newsletters, analyses, and podcasts—is free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. And such support is becoming more vital In light of current changes of funding and support for biomedical research at NIH and other US governmental agencies.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio and video support at Scripps Research. Get full access to Ground Truths at erictopol.substack.com/subscribe

Join Opie for a hilarious and heartfelt livestream with comedy legend Jackie "The Joke Man" Martling. Jackie shares unforgettable Howard Stern Show stories, from epic roasts and drunken chaos at the Grammys to the time he stormed off set. Hear how he sold jokes to Rodney Dangerfield, quit drinking cold turkey, and witnessed Sam Kinison’s electrifying early gigs and infamous Westbury meltdown. Plus, discover why Jackie’s house keeps landing in TV shows like Amazon’s The Better Sister. Visit Jokeland.com for Jackie’s upcoming stand-up comedy gigs and grab personalized Cameos at cameo.com/jackiemartling. See omnystudio.com/listener for privacy information.

Levi Wilson is BACK to discuss another controversial food song in Al's catalogue.... Grapefruit Diet! Is this song outdated and offensive or secretly brilliant? All this and some mediocre Rodney Dangerfield impressions on Weird Al-Gorithm! Learn more about your ad choices. Visit megaphone.fm/adchoices

GGACP celebrates the birthday of best-selling author and pop culture historian Kliph Nesteroff (b. February 20) by revisiting this classic (and frequently hilarious) interview from 2016. In this episode, Kliph joins Gilbert and Frank (along with recurring guest Drew Friedman) for an informative analysis of topics covering ten decades of popular entertainment, including: the dark secrets of vaudeville, the tragic childhood of Eddie Cantor, the phenomenon of Martin & Lewis and the strange death of “Parkyakarkus.” Also, Jack Benny swipes his stage name, Rodney Dangerfield runs afoul of the feds, Don Knotts sends up Hugh Hefner and the mob releases a comedy album. PLUS: Batman & Rubin! “The Baileys of Balboa”! Aunt Esther goes electric! And the angriest man in showbiz history! Learn more about your ad choices. Visit megaphone.fm/adchoices

...Jimmy Failla explains in episode #721 of The ANEZ SEZ podcast...

GGACP joins "Saturday Night Live"s 50th anniversary celebration with this ENCORE of a 2021 interview with comedian, Emmy-nominated writer, "Amazing Colossal Podcast" fan and original "SNL" cast member Laraine Newman. In this episode, Laraine talks about descending from Jewish cowboys, co-founding The Groundlings, auditioning for Bob Hope (and Robert De Niro) and penning her engrossing memoir, “May You Live in Interesting Times.” Also, Don Ameche mounts a comeback, Chevy Chase tells the “Aristocrats” joke, Laraine crushes on Illya Kuryakin and Walter Matthau turns down the Julia Child sketch. PLUS: Autumn Fizz! “American Hot Wax”! Buck Henry gets kinky! “That's Not Funny, That's Sick!” And Laraine recalls working with Bob & Ray, Dudley Moore and Rodney Dangerfield! Learn more about your ad choices. Visit megaphone.fm/adchoices

VP debate. Rodney Dangerfield and astrologer Joyce Jillson died. (I'm dying over here!) POLL: Which of these things would you most hate being thought of as? Howard Stern deal with SiriusXM announced.

This week, Chad and Justin review a Rodney Dangerfield comedy where he (probably) gets no respect. It's the 1986 film "Back to School"!   Like the show? Please leave a rating wherever you found us! Download and listen today on Apple Podcasts, Spotify, iHeart, Amazon, Stitcher, Goodpods, and more of your favorite podcast services! 

Dennis Blair's journey into comedy started by accident—but what a ride it's been. Originally a musician and songwriter, Blair stumbled into stand-up when his musical parodies unexpectedly stole the show. That moment of unexpected laughter led him to open for comedy icons, work alongside legends like Rodney Dangerfield and George Carlin, and write for some of the biggest names in entertainment. With a career spanning decades, Blair shares unforgettable behind-the-scenes stories, from writing Rappin' Rodney to witnessing the quirks of some of Hollywood's most legendary comedians.   Episode Highlights: Opening for Legends – Rodney Dangerfield discovered Blair early on, leading to years of touring with him, Joan Rivers, and George Carlin. Behind the Scenes of Easy Money – Writing for Dangerfield meant constant joke revisions and hilarious Hollywood chaos. Rodney's Wildest Moments – From limo rides gone wrong to infamous wardrobe malfunctions, Blair saw it all. From Comedy Clubs to Concert Arenas – Blair's musical comedy act made him the perfect opener for The Beach Boys, Barry Manilow, Gloria Estefan, and more. Writing for the Greats – A tag here, a punchline there—Blair even contributed jokes to Carlin's act, an honor for any comedian. Touring with Legends – His book shares untold stories of life on the road with entertainment's biggest names.   You're going to love my conversation with Dennis Blair Website Book: Touring with Legends Facebook Instagram YouTube Follow Jeff Dwoskin (host): Jeff Dwoskin on Twitter The Jeff Dwoskin Show podcast on Twitter Podcast website Podcast on Instagram Join my mailing list Subscribe to my Youtube channel (watch Crossing the Streams!) Yes, the show used to be called Live from Detroit: The Jeff Dwoskin Show Ways to support the show: Buy me a coffee (support the show) TeePublic Store: Classic Conversations merch and more! Love the books I talk about on the show? Here is my Amazon store to shop.  

This week, we're going back to school (but not like Rodney Dangerfield) to answer the question: What classes do we wish we could have taken? Because, in hindsight, there's a lot of energy we spent memorizing the quadratic equation that could have been directed to something more useful. Plus, Ann doesn't like Nate Bargatze, Bobby once met D. Woods, Hillary's a Teen Mom*, and, in a few months, Meredith will be, too**.*mother of a teen**mother of a teen catTSHE RecommendsTo Kill a MockingbirdConnect with the show!This is your show, too. Feel free to drop us a line, send us a voice memo, or fax us a butt to let us know what you think.Facebook group: This Show Has EverythingEmail: tsheshow@gmail.com 

(00:00-15:56) Ed Hermann joins us in studio. Doug's worried his computer is spying on him again. CC Sabathia in the HoF. Audio of Bill Dewitt at Winter Warm Up talking about payroll. Owners trying to win, not make money. Reinvesting back into the teams. Ed's got some shares of the Atlanta Braves. The power structure of the NL Central. (16:05-33:23) TV Voice of the Blues, John Kelly joins us. JK missing Vegas already. Eight way chops. Blues get out of Vegas with a big win in OT. Coaches sending messages to players. The Vegas Game Day experience. Martin looking like Wilson from Home Improvement. Rodney Dangerfield. Lou Holtz. (33:33-46:48) Jackson's airing of grievances. His sleeping arrangements for his trip. He's not happy with the Marquette fans reaction to the home loss. So many inaccuracies. A floatation cummerbund. Seeds of a take not quite ready to blossom. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(00:00-15:56) Ed Hermann joins us in studio. Doug's worried his computer is spying on him again. CC Sabathia in the HoF. Audio of Bill Dewitt at Winter Warm Up talking about payroll. Owners trying to win, not make money. Reinvesting back into the teams. Ed's got some shares of the Atlanta Braves. The power structure of the NL Central. (16:05-33:23) TV Voice of the Blues, John Kelly joins us. JK missing Vegas already. Eight way chops. Blues get out of Vegas with a big win in OT. Coaches sending messages to players. The Vegas Game Day experience. Martin looking like Wilson from Home Improvement. Rodney Dangerfield. Lou Holtz. (33:33-46:48) Jackson's airing of grievances. His sleeping arrangements for his trip. He's not happy with the Marquette fans reaction to the home loss. So many inaccuracies. A floatation cummerbund. Seeds of a take not quite ready to blossom. Learn more about your ad choices. Visit podcastchoices.com/adchoices

GGACP celebrates the 35th anniversary of one of Frank's favorite New York movies, the Bill Murray-directed bank heist flick "Quick Change," (released in January, 1990) by revisiting this conversation about the under-appreciated comedy. Also in this episode: Bob & Ray! The cinema of Rodney Dangerfield! Gilbert co-stars with Randy Quaid — and a Rottweiler! And the boys look back at the 1932 horror classic, "Freaks"! Learn more about your ad choices. Visit megaphone.fm/adchoices

Comedian Patton Oswalt (A.P. Bio, Mystery Science Theater 3000) joins Paul, June, and Jason to discuss the 1992 sports-comedy Ladybugs starring Rodney Dangerfield. They talk about the lady who faints in the dressing room scene, Jackee's sub-eating technique, and Rodney breaking into song for no reason. Plus, a special guest from the movie gives us insight from being on set during audience Q&A! (Originally Released 03/02/2018) Tix for our Spring 2025 tour in Austin, Denver, Seattle, Boise, San Fran, Portland, & Los Angeles are on sale now at hdtgm.com.Order Paul's book about his childhood: Joyful Recollections of TraumaFor extra content on Matinee Monday movies, visit Paul's YouTube page: youtube.com/paulscheerTalk bad movies on the HDTGM Discord: discord.gg/hdtgmPaul's Discord: discord.gg/paulscheerFollow Paul's movie recs on Letterboxd: letterboxd.com/paulscheer/Check out new HDTGM movie merch over at teepublic.com/stores/hdtgmPaul and Rob Huebel stream live on Twitch every Thursday 8-10pm EST: www.twitch.tv/friendzoneLike good movies too? Subscribe to Unspooled with Paul and Amy Nicholson: listen.earwolf.com/unspooledSubscribe to The Deep Dive with Jessica St. Clair and June Diane Raphael: www.thedeepdiveacademy.com/podcastWhere to find Paul, June, & Jason:@PaulScheer on Instagram & Twitter@Junediane on IG and @MsJuneDiane on TwitterJason is not on social mediaGet access to all the podcasts you love, music channels and radio shows with the SiriusXM App! Get 3 months free using the link: siriusxm.com/hdtgm.